CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Fundamental Analysis

NASDAQ:CYCC • US23254L8019

6.365 USD
-0.4 (-5.98%)
At close: Sep 11, 2025
6.4 USD
+0.04 (+0.55%)
After Hours: 9/11/2025, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

CYCC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. While CYCC seems to be doing ok healthwise, there are quite some concerns on its profitability. CYCC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year CYCC has reported negative net income.
  • CYCC had a negative operating cash flow in the past year.
  • CYCC had negative earnings in each of the past 5 years.
  • CYCC had a negative operating cash flow in each of the past 5 years.
CYCC Yearly Net Income VS EBIT VS OCF VS FCFCYCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • CYCC has a worse Return On Assets (-146.06%) than 84.29% of its industry peers.
  • CYCC has a Return On Equity of -177.03%. This is in the lower half of the industry: CYCC underperforms 64.88% of its industry peers.
Industry RankSector Rank
ROA -146.06%
ROE -177.03%
ROIC N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYCC Yearly ROA, ROE, ROICCYCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • CYCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCC Yearly Profit, Operating, Gross MarginsCYCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • CYCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CYCC has been increased compared to 1 year ago.
  • Compared to 5 years ago, CYCC has more shares outstanding
  • There is no outstanding debt for CYCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYCC Yearly Shares OutstandingCYCC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
CYCC Yearly Total Debt VS Total AssetsCYCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • CYCC has an Altman-Z score of -136.20. This is a bad value and indicates that CYCC is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -136.20, CYCC is doing worse than 96.86% of the companies in the same industry.
  • There is no outstanding debt for CYCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -136.2
ROIC/WACCN/A
WACC9.66%
CYCC Yearly LT Debt VS Equity VS FCFCYCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

  • A Current Ratio of 5.77 indicates that CYCC has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 5.77, CYCC is in the better half of the industry, outperforming 61.55% of the companies in the same industry.
  • CYCC has a Quick Ratio of 5.77. This indicates that CYCC is financially healthy and has no problem in meeting its short term obligations.
  • CYCC has a Quick ratio of 5.77. This is in the better half of the industry: CYCC outperforms 61.74% of its industry peers.
Industry RankSector Rank
Current Ratio 5.77
Quick Ratio 5.77
CYCC Yearly Current Assets VS Current LiabilitesCYCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • CYCC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.85%, which is quite impressive.
  • CYCC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.50%.
EPS 1Y (TTM)96.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
Revenue 1Y (TTM)-87.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • CYCC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.35% yearly.
  • The Revenue is expected to grow by 385.15% on average over the next years. This is a very strong growth
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%

3.3 Evolution

CYCC Yearly Revenue VS EstimatesCYCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CYCC Yearly EPS VS EstimatesCYCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5K -10K -15K -20K -25K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • CYCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CYCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCC Price Earnings VS Forward Price EarningsCYCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCC Per share dataCYCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

  • CYCC's earnings are expected to grow with 57.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CYCC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CYCLACEL PHARMACEUTICALS INC

NASDAQ:CYCC (9/11/2025, 8:00:01 PM)

After market: 6.4 +0.04 (+0.55%)

6.365

-0.4 (-5.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12
Earnings (Next)11-10
Inst OwnersN/A
Inst Owner Change48.05%
Ins OwnersN/A
Ins Owner Change30.81%
Market Cap14.26M
Revenue(TTM)10.00K
Net Income(TTM)-6.43M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)-37.21%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-50.98%
Min Revenue beat(4)-100%
Max Revenue beat(4)96.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1425.76
P/FCF N/A
P/OCF N/A
P/B 3.93
P/tB 3.93
EV/EBITDA N/A
EPS(TTM)-122.02
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-3.9
FCFYN/A
OCF(TTM)-3.9
OCFYN/A
SpS0
BVpS1.62
TBVpS1.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -146.06%
ROE -177.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.77
Quick Ratio 5.77
Altman-Z -136.2
F-Score3
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue 1Y (TTM)-87.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%
EBIT growth 1Y48.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y57.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.04%
OCF growth 3YN/A
OCF growth 5YN/A

CYCLACEL PHARMACEUTICALS INC / CYCC FAQ

What is the fundamental rating for CYCC stock?

ChartMill assigns a fundamental rating of 3 / 10 to CYCC.


What is the valuation status for CYCC stock?

ChartMill assigns a valuation rating of 1 / 10 to CYCLACEL PHARMACEUTICALS INC (CYCC). This can be considered as Overvalued.


How profitable is CYCLACEL PHARMACEUTICALS INC (CYCC) stock?

CYCLACEL PHARMACEUTICALS INC (CYCC) has a profitability rating of 0 / 10.


Can you provide the financial health for CYCC stock?

The financial health rating of CYCLACEL PHARMACEUTICALS INC (CYCC) is 6 / 10.